Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual Meeting – courtesy of the Lymphoma Hub.

Find out more


Stock quote


News


Events


This site uses cookies to improve user experience by collecting data. Please click 'Accept all and continue' to consent to our use of cookies or go to Privacy Settings to view the types of information collected and set your browsing preferences.